PLXDC1 and neoplasm: To target PLXDC1 as an effective therapeutic gene in tumor endothelial cells, we selected siRNA-based treatment strategy that could specifically knock down the target gene and was nontoxic to other sequences, even in normal cells (Mangala et al., 2009; Han et al., 2010).